Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. / Registro de linfomas cutáneos primarios (RELCP) de la AEDV: datos tras 5 años de funcionamiento.

BACKGROUND AND OBJECTIVE: Primary cutaneous lymphomas (PCL) are uncommon. Observations based on the first year of data from the Spanish Registry of Primary Cutaneous Lymphomas (RELCP, in its Spanish abbreviation) of the Spanish Academy of Dermatology and Venereology (AEDV) were published in February 2018. This report covers RELCP data for the first 5 years. PATIENTS AND METHODS: RELCP data were collected prospectively and included diagnosis, treatments, tests, and the current status of patients. We compiled descriptive statistics of the data registered during the first 5 years. RESULTS: Information on 2020 patients treated at 33 Spanish hospitals had been included in the RELCP by December 2021. Fifty-nine percent of the patients were men; the mean age was 62.2 years. The lymphomas were grouped into 4 large diagnostic categories: mycosis fungoides/Sézary syndrome, 1112 patients (55%); primary B-cell cutaneous lymphoma, 547 patients (27.1%); primary CD30+lymphoproliferative disorders, 222 patients (11%), and other T-cell lymphomas, 116 patients (5.8%). Nearly 75% of the tumors were registered in stage I. After treatment, 43.5% achieved complete remission and 27% were stable at the time of writing. Treatments prescribed were topical corticosteroids (1369 [67.8%]), phototherapy (890 patients [44.1%]), surgery (412 patients [20.4%]), and radiotherapy (384 patients [19%]). CONCLUSION: The characteristics of cutaneous lymphomas in Spain are similar to those reported for other series. The large size of the RELCP registry at 5 years has allowed us to give more precise descriptive statistics than in the first year. This registry facilitates the clinical research of the AEDV's lymphoma interest group, which has already published articles based on the RELCP data.

Elevación de seno conBetafosfato Tricálcico yposterior colocación deimplantes. A propósito deun caso / Sinus lift with tricalcium beta-phosphate and subsequent implant placement. Case report

La extracción o pérdida dental supone la remodelación del alveolo y una pérdida progresiva del hueso alveolar residual. Esta disminución en altura, debido a la presencia delseno maxilar en el sector posterosuperior, puede comprometer la disponibilidad ósea adecuada para la colocación de implantes. Como solución a esto, surge la técnica de elevación de seno. En esta técnica, se emplean diversos materiales de injerto, entre los que se encuentran el betafosfatotricálcico (b-TCP). Este material presenta propiedades osteoconductivas y osteoinductivas. Además, se reabsorbe más fácil que otros sustitutos óseos y es fácilmente reemplazado por nuevo hueso. Se ha comparado su comportamiento clínico con otros materiales de injerto, sin encontrar diferencias significativas. Además, a 10 años, los implantes colocados en elevaciones de seno realizadas con b-TCP han mostrado altas tasas de supervivencia. Caso clínico. Se presenta el caso clínico de una paciente, mujer de 52 años de edad, sin antecedentes médicos de interés. Acude a consulta por dolor en el 26. Tras la exploración diagnóstica radiológica e intrabucal se aconsejó a la paciente la extracción del 26. Ocho meses después, y realizando un estudio con CBCT se informó a la paciente sobre la posibilidad de rehabilitación con implantes, previa cirugía de elevación sinusal. Se realizó la elevación sinusal con b-TCP como material de injerto. Pasados tres meses, se procedió a la colocación de tres implantes, adquiriendo estos una buena estabilidad primaria Discusión y conclusiones. Se utilizan diversos materiales de injerto en la técnica de elevación sinusal, injertos de hueso autólogo, xenoinjertos e injerto aloplásticos. Se ha comparado el comportamiento clínico del b-TCP con otros materiales de injerto sin mostrar diferencias significativas. Por otro lado, se ha estudiado un periodo de espera menor a 6 (AU)

Tooth extraction or loss involves alveolar remodelling and progressive loss of residual alveolar bone. This reduction in height, due to the presence of the maxillary sinus in the posterosuperior sector, can compromise adequate bone availability for implant placement. The sinus lift technique has emerged as a solution to this problem. In this technique, various grafting materials are used, including beta-phosphatidic acid (b-TCP). This material has osteoconductive and osteoinductive properties. In addition, it is more easily resorbed than other bone substitutes and is easily replaced by new bone. Its clinical behaviour has been compared with other graft materials, without finding significant differences. In addition, at 10 years, implants placed in sinus lifts performed with b-TCP have shown high survival rates. Clinical case: The clinical case of a 52-year-old female patient with no medical history of interest is presented. She went for consultation due to pain in tooth 26. Following the radiological and intraoral diagnostic examination, the patient was advised to have tooth 26 extracted. Eight months later, and after a CBCT study, the patient was informed about the possibility of rehabilitation with implants, following sinus lift surgery. The sinus lift was performed with b-TCP as graft material. After three months, three implants were placed, acquiring a good primary stability. Discussion and conclusions: different graft materials are used in the sinus lift technique, autologous bone grafts, xenografts and alloplastic grafts. The clinical performance of b-TCP has been compared with no significant differences found. Furthermore, a waiting period of less than 6 months has been studied for the placement of implants. These implants showed high primary stability and survival rates of 99-100%. Therefore, b-TCP is a safe material for sinus lifts and allows the placement of implants in a healing time of less than 6 months (AU)

Escaldadura estafilocócica recurrente. ¿Existe algo más? / Recurrent staphylococcal scalded skin syndrome. Is there something else?

No disponible

Ética en el control perinatal en relación a mortalidad materna en el Perú, 2007 / Ethics in perinatal control in relation to maternal mortality in Peru, 2007

INTRODUCCIÓN: La mayoría de muertes maternas se producen en países en vías de desarrollo; Perú el año 2007 fue el segundo país con la más alta tasa de mortalidad materna en Sudamérica, lo cual podría deberse a un déficit en la cobertura y la calidad de los servicios de salud. OBJETIVO: Evaluar la relación estadística entre el control perinatal y la mortalidad materna por departamentos en el Perú. MATERIAL Y MÉTODO: Estudio ecológico con corte transversal bivariado. Se estudiaron la razón de mortalidad materna y 6 indicadores del control perinatal (primera atención prenatal durante el primer trimestre de gestación, partos institucionales, entre otros) del año 2007 por departamentos en el Perú. La información se obtuvo de fuentes oficiales: Encuesta Nacional Demográfica y de Salud familiar y Ministerio de Salud. Se utilizó el programa Epidat 3.1. Se determinó Odds ratio y chi cuadrado y un nivel de confianza del 95 por ciento. RESULTADOS: Únicamente se encontró asociación estadísticamente significativa (p<0,05) entre mortalidad materna con: primera atención prenatal durante el primer trimestre de gestación, partos institucionales, partos atendidos por personal calificado y atención postnatal. Sólo se pudo calcular el Odds ratio para atención postnatal: probabilidad del 95,45 por ciento de que exista una alta razón de mortalidad materna cuando existe una pobre cobertura de atenciones postnatales. DISCUSIÓN: En el Perú, la poca cobertura de primera atención durante el primer trimestre, partos institucionales, y partos por profesional calificado están asociados a mortalidad materna. Un especial interés debe existir en la prevención de la mortalidad materna mejorando la atención postnatal.

INTRODUCTION: Most maternal deaths occur in developing countries, Peru was the second country with the highest maternal mortality rate in South America in 2007, which could be dueto gaps in coverage and quality of health services. OBJECTIVE: To evaluate the statistical relationship between perinatal care and maternal mortality in the departments of Peru. MATERIALAND METHOD: transversal bivariate ecological study. Maternal mortality ratio at 2007 and its relation to 6 indicators of perinatal care (first prenatal care during the first trimester of pregnancy, institutional births, among others) were studied using departments as analysis unit. The information was obtained from official sources: Encuesta demográfica y de salud familiar 2007 and Ministerio de Salud. Software Epidat 3.1 was used for the analysis. Odds ratio and chi squared were obtained with a confidence level of 95 percent. RESULTS: It was only found statistically significant association (p <0.05) between maternal mortality and first prenatal care during the first trimester of pregnancy, institutional births, births attended by skilled staff and postnatal care. It was only possible to calculate Odds ratio for postnatal care indicator, which showed 95.45 percent of probability of higher maternal mortality rate when there is poor postnatal care coverage. DISCUSSION: In Peru, the low coverage of first prenatal care during the first trimester of pregnancy, institutional births and births attended by qualified personnel are associated to maternal mortality. Postnatal care should be considered with special interest in order to prevent maternal mortality.

Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.

BACKGROUND: Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients. OBJECTIVES: To evaluate the effectiveness, tolerance and adverse effects of ILR in patients with follicle centre (FCL) and marginal zone (MZL) PCBL. METHODS: This was an epidemiological observational multicentre study of patients with PCBL treated with ILR. RESULTS: Seventeen patients with MZL and 18 with FCL PCBL were included. The median number of lesions treated was two per patient. The treatment regimen used in 74% of the patients was a course of three injections in a single week at 1-month intervals. The dose per lesion and day of treatment was 10 mg in 71% of the patients. The median cumulative dose of rituximab per lesion was 60 mg (range 13-270) and per patient was 150 mg (range 20-360 mg). Complete response (CR) and partial response were achieved in 71% and 23% of patients, respectively. The median time to CR in patients who received 10 mg of ILR per lesion was 8 weeks. Similar response rates were observed in MZL and FCL. Median disease-free survival was 114·1 weeks. No parameters that significantly predicted CR were identified. Adverse reactions were recorded in 19 patients; the most frequent was localized pain at the injection site. Median follow-up was 21 months. CONCLUSIONS: Intralesional rituximab is a well-tolerated and effective treatment for FCL and MZL PCBL. It should be considered a useful alternative in patients with recurrent lesions and in which the sequelae of radiotherapy or surgery would be significant.

Dermatitis de contacto por textiles en paciente sensibilizada al tinte Reactive Orange 107 / Textile contact dermatitis in a patient sensitized to Reactive Orange 107 dye

No disponible

No disponible

Hematoma profundo disecante o estadio IV de dermatoporosis / Deep dissecting hematoma or stage IV dermatoporosis

No disponible

No disponible

Linfoma cutáneo de células B del centro folicular tratado con rituximab intralesional / Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab

Los linfomas cutáneos de células B del centro folicular son tumores indolentes compuestos por células neoplásicas del centro folicular. Están constituidos por una mezcla de centrocitos con un número variable de centroblastos. Los tratamientos habitualmente utilizados son la cirugía y la radioterapia, aunque se utilizan otros como el interferón-a (IFN-a), la quimioterapia y tratamientos biológicos (rituximab). El rituximab es un anticuerpo monoclonal quimérico anti-CD20. Puede utilizarse por vía intravenosa o intralesional. Presentamos el caso de un paciente varón de 41 años que consultó por lesiones nodulares violáceas en el área escapular izquierda y que, tras la realización de una biopsia, analítica, tomografía axial computarizada (TAC) toracoabdominopélvica, ecografía abdominal y biopsia de médula ósea fue diagnosticado de linfoma cutáneo de células B del centro folicular. Se decidió tratamiento con 30 mg de rituximab intralesional, tres veces a la semana, una vez al mes, durante 4 meses, con respuesta completa. Realizamos una revisión de los casos de linfoma cutáneo de células B tratados con rituximab intralesional (AU)

Cutaneous follicular center B-cell lymphomas are indolent tumors characterized by the presence of neoplastic follicular center cells. They contain a mixture of centrocytes with a variable number of centroblasts. The tumor is usually treated by surgery or radiotherapy, although other treatments may be used such as interferon-a, chemotherapy, and biological agents (rituximab). Rituximab is a chimeric monoclonal anti-CD20 antibody that can be administered intravenously or intralesionally. We report the case of a 41-year-old man who consulted for violaceous nodular lesions in the left scapular region and who was diagnosed with cutaneous follicular center B-cell lymphoma after biopsy, laboratory tests, thoracic-abdominal-pelvic computed tomography, abdominal ultrasound, and bone marrow biopsy. It was decided to treat him with 30 mg of intralesional rituximab administered for 1 week (3 times) every month for 4 months. Complete response was obtained. We also review the published cases of cutaneous B-cell lymphoma treated with intralesional rituximab (AU)

[Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab]. / Linfoma cutáneo de células B del centro folicular tratado con rituximab intralesional.

Cutaneous follicular center B-cell lymphomas are indolent tumors characterized by the presence of neoplastic follicular center cells. They contain a mixture of centrocytes with a variable number of centroblasts. The tumor is usually treated by surgery or radiotherapy, although other treatments may be used such as interferon-alpha, chemotherapy, and biological agents (rituximab). Rituximab is a chimeric monoclonal anti-CD20 antibody that can be administered intravenously or intralesionally. We report the case of a 41-year-old man who consulted for violaceous nodular lesions in the left scapular region and who was diagnosed with cutaneous follicular center B-cell lymphoma after biopsy, laboratory tests, thoracic-abdominal-pelvic computed tomography, abdominal ultrasound, and bone marrow biopsy. It was decided to treat him with 30 mg of intralesional rituximab administered for 1 week (3 times) every month for 4 months. Complete response was obtained. We also review the published cases of cutaneous B-cell lymphoma treated with intralesional rituximab.

Erupción vesiculosa asociada a inyección conjuntival / Vesicular eruption associated with conjunctival injection

No disponible

No disponible

[Dermatomyositis and punctate porokeratotic keratoderma as paraneoplastic syndrome of ovarian carcinoma]. / Dermatomiositis y queratodermia poroqueratósica punctata como síndrome paraneoplásico de un carcinoma ovárico.

Dermatomyositis (DM) is a dermatomyopathy with a broad spectrum of features, defined by Bohan et al as an objective set of clinical and laboratory criteria. Dermatomyositis has been associated with extracutaneous neoplasias, especially with ovarian carcinoma. The term <> comprises a group of diseases with different etiologies characterized by small hyperkeratotic lesions usually scattered in palms and soles. Punctate porokeratotic keratoderma (PPK) is a type of punctate keratoderma mainly defined by its peculiar histological features, including the presence of cornoid lamella similar to the one observed in porokeratosis. Punctate porokeratotic keratoderma has been considered a sporadic disease although some rare paraneoplastic cases have been published. We report for the first time a case of dermatomyositis with typical features of punctate porokeratotic keratoderma, both as paraneoplastic presentation of ovarian carcinoma. Its paraneoplastic nature is clearly demonstrated by the clinical improvement observed following tumor excision.

Dermatomiositis y queratodermia poroqueratósica punctata como síndrome paraneoplásico de un carcinoma ovárico / Dermatomyositis and punctate porokeratotic keratoderma as paraneoplastics syndrome of ovarian carcinoma

La dermatomiositis (DM) es una dermatomiopatía con un amplio espectro de manifestaciones, definido por Bohan et al como un conjunto objetivo de criterios clínico-analíticos. La DM se ha relacionado con neoplasias extracutáneas, especialmente con carcinoma ovárico. El término queratodermia punctata incluye un grupo de enfermedades con diferentes etiologías, caracterizadas por lesiones hiperqueratósicas de pequeño tamaño, habitualmente salpicadas en palmas y plantas. La queratodermia poroqueratósica punctata (QPP) es un tipo de queratodermia punctata definida principalmente por sus peculiares características histopatológicas, incluyendo la presencia de lamela cornoide, similar a la observada en la poroqueratosis. La QPP ha sido considerada una enfermedad esporádica; sin embargo se ha publicado algún caso raro paraneoplásico. Presentamos por vez primera un caso de DM con datos típicos de QPP, ambas como manifestaciones paraneoplásicas de un carcinoma ovárico. Su naturaleza paraneoplásica es claramente demostrada por la mejoría clínica observada tras la extirpación de la neoplasia

Dermatomyositis (DM) is a dermatomyopathy with a broad spectrum of features, defined by Bohan et al as an objective set of clinical and laboratory criteria. Dermatomyositis has been associated with extracutaneous neoplasias, especially with ovarian carcinoma. The term «punctate keratoderma» comprises a group of diseases with different etiologies characterized by small hyperkeratotic lesions usually scattered in palms and soles. Punctate porokeratotic keratoderma (PPK) is a type of punctate keratoderma mainly defined by its peculiar histological features, including the presence of cornoid lamella similar to the one observed in porokeratosis. Punctate porokeratotic keratoderma has been considered a sporadic disease although some rare paraneoplastic cases have been published. We report for the first time a case of dermatomyositis with typical features of punctate porokeratotic keratoderma, both as paraneoplastic presentation of ovarian carcinoma. Its paraneoplastic nature is clearly demonstrated by the clinical improvement observed following tumor excision